PROTHENACORP PLC
Aktie · IE00B91XRN20 · PRTA · A1KAVV (XNMS)
Kein Kurs
12.12.2025 21:44
Aktuelle Kurse von PROTHENACORP PLC
| Börse | Ticker | Währung | Letzter Umsatz | Kurs | Tagesveränderung |
|---|---|---|---|---|---|
![]() NASDAQ |
PRTA
|
USD
|
12.12.2025 21:44
|
10,30 USD
| -0,03 USD
-0,29 %
|
![]() Frankfurt |
0PT.F
|
EUR
|
12.12.2025 20:45
|
8,65 EUR
| 0,45 EUR
+5,49 %
|
![]() Quotrix |
PCPLCR20.DUSD
|
EUR
|
12.12.2025 06:27
|
8,80 EUR
| 0,60 EUR
+7,32 %
|
![]() Düsseldorf |
PCPLCR20.DUSB
|
EUR
|
11.12.2025 18:30
|
8,50 EUR
| -0,20 EUR
-2,30 %
|
Investierte Fonds
Folgende Fonds haben in PROTHENACORP PLC investiert:
Fonds | Vol. in Mio 107,09 | Anteil (%) 0,25 % |
Firmenprofil zu PROTHENACORP PLC Aktie
Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing Birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, which is in Phase IIb clinical trial for the treatment of Parkinson's disease; PRX004 that completed Phase I clinical trial for the treatment of Transthyretin amyloidosis; and PRX005, which is in Phase I clinical trial for the treatment of Alzheimer's disease. Its discovery and preclinical programs include PRX012 for the treatment of Alzheimer's disease; and dual Aß-Tau vaccine for the treatment and prevention of Alzheimer's disease. Prothena Corporation plc has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target alpha-synuclein; and a collaboration agreement with Bristol-Myers Squibb to develop antibodies. The company was founded in 2012 and is based in Dublin, Ireland.
Unternehmensdaten
Name PROTHENACORP PLC
Firma Prothena Corporation plc
Symbol PRTA
Website
https://www.prothena.com
Heimatbörse
NASDAQ/NMS (GLOBAL MARKET)
WKN A1KAVV
ISIN IE00B91XRN20
Wertpapierart Aktie
Sektor Healthcare
Branche Biotechnology
CEO Gene G. Kinney
Marktkapitalisierung 557 Mio
Land Irland
Währung USD
Mitarbeiter 0,2 T
Adresse 77 Sir John Rogerson’s Quay, 2 Dublin
IPO Datum 2012-12-18
Ticker Symbole
| Name | Symbol |
|---|---|
| Düsseldorf | PCPLCR20.DUSB |
| Frankfurt | 0PT.F |
| NASDAQ | PRTA |
| Quotrix | PCPLCR20.DUSD |
Weitere Aktien
Investoren, die PROTHENACORP PLC halten, haben auch folgende Aktien im Depot:
Die Finanzplattform MoneyPeak trackt und analysiert Investitionen und Portfolios.
Vom Wertpapier-Depot bis zum Crypto-Kauf.
Nützlich, simpel und kostenlos. Aktien, ETF, ETC, ETN, Indizes, Fonds, Anleihen, Zertifikate, Währungen, Optionen, Bezugsrechte.
Nützlich, simpel und kostenlos. Aktien, ETF, ETC, ETN, Indizes, Fonds, Anleihen, Zertifikate, Währungen, Optionen, Bezugsrechte.








